Janssen-Cilag GmbH

General information
Janssen-Cilag GmbH
Johnson & Johnson Platz 1
41470 Neuss, North Rhine-Westphalia

Contact person: Peter Solberg, Managing Director
Company main phone: +49 (2137) 9550
Company main fax:  +49 (2137) 955327
Website:  www.janssen-cilag.de
Year founded:1959
Source of foundation:Subsidiary
Name of foundation source:Johnson & Johnson
No. of employees: Worldwide:  40000
Corporate description / mission:
Janssen-Cilag GmbH manufactures and markets pharmaceutical products. The company is dedicated to addressing and solving the most important unmet medical needs including oncology (multiple myeloma and prostate cancer), immunology (psoriasis), neuroscience (schizophrenia, dementia, pain), infectious diseases (HIV/AIDS, hepatitis C, tuberculosis), and cardiovascular and metabolic diseases (diabetes).
State of ownership: Subsidiary
Headquarters: No
Remarks on ownership / listings
Janssen-Cilag, a subsidiary of the healthcare group Johnson & Johnson is an international research-based pharmaceutical company.
  • Pharma (fully integrated)
  • Anti-infectives
  • Vaccines
  • Other
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the nervous system / neurology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Mental and behavioural disorders / psychiatry /psychology
  • Neoplasms / cancer / oncology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • Manufacturer
  • R&D
  • Subsidiary
  • Supplier / Distributor
Customer segments:
  • Consumers (mass market)
  • Hospitals
  • Physicians / doctors
  • Direct (own sales force)
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Description of products:
Erypo FS®
Stelara®, etc.